Trevi Therapeutics, Inc.
NASDAQTRVI heads into its August 10 earnings report with a notable analyst consensus shift as the stock trades near a multi-month high. The most striking feature of the pre-earnings setup is the direction of analyst opinion. Coverage has turned decisively constructive in the past three weeks. BMO Capital initiated with an Outperform rating and a $36 target on July 21 — the most bullish…
Snapshot as of 20 Sept 2026
TRVI heads into its August 10 earnings report with a notable analyst consensus shift as the stock trades near a multi-month high. The most striking feature of the pre-earnings setup is the direction of analyst opinion.…
Trevi Therapeutics enters the final stretch before its June 3 catalysts with a sharp 10.3% weekly decline creating a notable tension: every analyst still rates the stock a buy, yet the market has pulled it down 13% in…
Trevi Therapeutics enters its May 7 earnings release with a meaningful short base still in place, even as the stock has rebounded sharply and the lending market suggests bears are not pressing harder. Short sellers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TRVI — free to start on ORTEX.
Sign up for free →Open TRVI on ORTEX